NRXP

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

Wall Street analysts forecast NRXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXP is 33.00 USD with a low forecast of 25.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NRX Pharmaceuticals Inc revenue for the last quarter amounts to 242.00K USD, decreased % YoY.

NRX Pharmaceuticals Inc. EPS for the last quarter amounts to -0.26 USD, increased 73.33 % YoY.

NRX Pharmaceuticals Inc (NRXP) has 0 emplpoyees as of December 18 2025.

Today NRXP has the market capitalization of 68.09M USD.